European patients with two forms of lymphoma now have access to a newly approved medication that works through a distinctive biological mechanism. On August 15, 2024, the European Union authorized Odronextamab, a drug marketed under the brand name Ordspono and developed by Regeneron Pharmaceuticals.
Odronextamab belongs to a class of therapies known as bispecific monoclonal antibodies. Unlike standard monoclonal antibodies that attach to a single target, this drug is engineered to bind to two different molecules simultaneously. Specifically, it connects to CD20, a protein found on cancerous B-cells, and CD3, a protein on immune T-cells. This dual binding is intended to direct the immune system to identify and destroy lymphoma cells, a task it often fails to perform on its own.
The approval covers two serious cancers of the immune system: follicular lymphoma and diffuse large B-cell lymphoma. Patients with these conditions may exhaust standard treatments such as chemotherapy and targeted drugs, only to experience a relapse. Each new therapeutic option, particularly one with a novel mechanism, provides physicians with an additional tool when existing therapies lose effectiveness.
The authorization follows clinical trials conducted by Regeneron that revealed several common side effects requiring careful management. The most frequently reported issue was cytokine release syndrome, a systemic inflammatory response that can resemble severe influenza or become more serious. Other adverse effects included infections, neutropenia, fever, anemia, thrombocytopenia, and diarrhea. While these side effects are significant, oncologists routinely manage similar complications in other cancer treatments, and many patients consider the potential benefits worthwhile.
Regeneron has a track record of pursuing complex biological targets. The company is recognized for its work on monoclonal antibodies, including treatments developed for Ebola and COVID-19. Odronextamab emerged from that same research pipeline, advancing through years of clinical development that assessed response rates and how long benefits lasted.
The broader field of bispecific antibodies remains relatively new. The first such drug for cancer received approval only a few years ago. Each new addition, including Odronextamab, reinforces the validity of this approach, demonstrating to researchers and investors that the mechanism functions, regulators accept it, and patients can tolerate it. This momentum may accelerate development of other bispecific therapies targeting different cancers.
For now, the focus remains on lymphoma. The EU approval gives European hematologists another treatment option. No single drug cures every patient, but this approval expands the available arsenal. For individuals who have seen their disease return after multiple treatment rounds, having another option represents more than a minor development—it offers a renewed chance.
